Cargando…

Adipose-derived stem cell therapy shows promising results for secondary lymphedema

Lymphedema is mainly identified by progressive soft tissue swelling in impaired lymphatic system. Secondary lymphedema attributed to cancer therapy, parasite infection, and trauma remains a serious global disease. Patients with lymphedema suffer swelling, pain, and fatigue, with the dysfunction of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Li-Ru, Pan, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415246/
https://www.ncbi.nlm.nih.gov/pubmed/32843917
http://dx.doi.org/10.4252/wjsc.v12.i7.612
_version_ 1783569132172607488
author Hu, Li-Ru
Pan, Jian
author_facet Hu, Li-Ru
Pan, Jian
author_sort Hu, Li-Ru
collection PubMed
description Lymphedema is mainly identified by progressive soft tissue swelling in impaired lymphatic system. Secondary lymphedema attributed to cancer therapy, parasite infection, and trauma remains a serious global disease. Patients with lymphedema suffer swelling, pain, and fatigue, with the dysfunction of the deformed extremities reducing the quality of life and increasing the risk of infection and lymphangiosarcoma. Adipose-derived stem cells (ADSCs) possess prominent regenerative potential to differentiate into multilineage cells, and produce various lymphangiogenic factors, making ADSC therapy a promising approach for lymphedema. The development of lymphedema consists of local inflammation, the fibrosis of lymphatic vessels, and the deposition of adipose fat. Existing animal models do not mimic the chronic inflammation environment, therefore suitable models are required in further studies. Some signal pathways and molecular mechanisms in physiological and pathological lymphagiogenesis remain unclear. In previous animal and human trials, ADSC therapy reduced edema in varying degrees. A larger number of trials with larger samples and longer follow-up periods are required to verify the efficiency and feasibility of ADSC therapy. ADSCs are of easy availability and immune exemption, making them a candidate for lymphedema treatment. Whether ADSCs enhance malignant characteristics or trigger the malignant change deserves further exploration and study before ADSC therapy can be made widely available.
format Online
Article
Text
id pubmed-7415246
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-74152462020-08-24 Adipose-derived stem cell therapy shows promising results for secondary lymphedema Hu, Li-Ru Pan, Jian World J Stem Cells Minireviews Lymphedema is mainly identified by progressive soft tissue swelling in impaired lymphatic system. Secondary lymphedema attributed to cancer therapy, parasite infection, and trauma remains a serious global disease. Patients with lymphedema suffer swelling, pain, and fatigue, with the dysfunction of the deformed extremities reducing the quality of life and increasing the risk of infection and lymphangiosarcoma. Adipose-derived stem cells (ADSCs) possess prominent regenerative potential to differentiate into multilineage cells, and produce various lymphangiogenic factors, making ADSC therapy a promising approach for lymphedema. The development of lymphedema consists of local inflammation, the fibrosis of lymphatic vessels, and the deposition of adipose fat. Existing animal models do not mimic the chronic inflammation environment, therefore suitable models are required in further studies. Some signal pathways and molecular mechanisms in physiological and pathological lymphagiogenesis remain unclear. In previous animal and human trials, ADSC therapy reduced edema in varying degrees. A larger number of trials with larger samples and longer follow-up periods are required to verify the efficiency and feasibility of ADSC therapy. ADSCs are of easy availability and immune exemption, making them a candidate for lymphedema treatment. Whether ADSCs enhance malignant characteristics or trigger the malignant change deserves further exploration and study before ADSC therapy can be made widely available. Baishideng Publishing Group Inc 2020-07-26 2020-07-26 /pmc/articles/PMC7415246/ /pubmed/32843917 http://dx.doi.org/10.4252/wjsc.v12.i7.612 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Hu, Li-Ru
Pan, Jian
Adipose-derived stem cell therapy shows promising results for secondary lymphedema
title Adipose-derived stem cell therapy shows promising results for secondary lymphedema
title_full Adipose-derived stem cell therapy shows promising results for secondary lymphedema
title_fullStr Adipose-derived stem cell therapy shows promising results for secondary lymphedema
title_full_unstemmed Adipose-derived stem cell therapy shows promising results for secondary lymphedema
title_short Adipose-derived stem cell therapy shows promising results for secondary lymphedema
title_sort adipose-derived stem cell therapy shows promising results for secondary lymphedema
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415246/
https://www.ncbi.nlm.nih.gov/pubmed/32843917
http://dx.doi.org/10.4252/wjsc.v12.i7.612
work_keys_str_mv AT huliru adiposederivedstemcelltherapyshowspromisingresultsforsecondarylymphedema
AT panjian adiposederivedstemcelltherapyshowspromisingresultsforsecondarylymphedema